Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 8, 2006

Coley and GSK Amend VaxImmune Agreement

  • Coley Pharmaceutical amended its strategic alliance license agreement with GlaxoSmithKline (GSK) for the use of Coley's VaxImmune™ vaccine adjuvant product in the development of certain infectious disease vaccines. As a result, Coley will be able to enter into additional nonexclusive licenses with other vaccine developers for the use of VaxImmune in infectious disease vaccines.

    Coley and GSK originally entered into a worldwide co-exclusive license for the use of Coley's VaxImmune vaccine adjuvant compound in certain therapeutic and prophylactic vaccines for infectious diseases in December 1998. The amendment enables Coley to license VaxImmune for use in virtually all infectious disease vaccines.

    There also was an adjustment to the financial terms, including a $17.4 million reduction in the potential regulatory and development milestones to be earned by Coley under the original $79.3-million infectious disease agreement.

    VaxImmune is a toll-like receptor 9 (TLR9) agonist designed to induce both an enhanced antibody response and a potent killer T-cell immune response to infection or tumors to achieve and sustain a clinical response without compromising safety.


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »